CoChat

Trial watch: TLR3 agonists in cancer therapy

Open access
Le Naour, Julie, Galluzzi, Lorenzo, Zitvogel, Laurence, Kroemer, Guido, Vacchelli, Erika · 2020 · OncoImmunology

The DOI matches its Crossref record; 408 of the 410 references it cites were found in a registry or an index.

Abstract

Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in endosomes. On activation, TLR3 initiates a signal transduction pathway that culminates with the secretion of pro-inflammatory cytokines including type I interferon (IFN). The latter is essential not only for innate immune responses to infection but also for the initiation of antigen-specific immunity against viruses and malignant cells. These aspects of TLR3 biology have supported the development of various agonists for use as stand-alone agents or combined with other therapeutic modalities in cancer patients. Here, we review recent preclinical and clinical advances in the development of TLR3 agonists for oncological disorders.Abbreviations cDC, conventional dendritic cell; CMT, cytokine modulating treatment; CRC, colorectal carcinoma; CTL, cytotoxic T lymphocyte; DC, dendritic cell; dsRNA, double-stranded RNA; FLT3LG, fms-related receptor tyrosine kinase 3 ligand; HNSCC, head and neck squamous cell carcinoma; IFN, interferon; IL, interleukin; ISV, in situ vaccine; MUC1, mucin 1, cell surface associated; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; polyA:U, polyadenylic:polyuridylic acid; polyI:C, polyriboinosinic:polyribocytidylic acid; TLR, Toll-like receptor

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2020.1771143

Cites

408 of 408 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Overview of STING signaling in cancer cells. Accumulation of double-stranded DNA (dsDNA) in the cytosol of cancer cells responding to some chemotherapeutics or radiation therapy boosts the enzymatic functions of cyclic GMP-AMP synthase (CGAS), resulting in the cyclic GMP-AMP (cGAMP)-dependent oligomerization and activation of stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) at the endoplasmic reticulum (ER). Activated STING promotes a TANK binding kinase 1 (TAK1)-dependent signal transduction cascade that initiates interferon regulatory factor 3 (IRF3)- and NF-κB-dependent transcription, potentially culminating with the secretion of numerous cytokines including type I interferon (IFN), interleukin 6 (IL-6) and tumor necrosis factor (TNF). CDN, cyclic dinucleotide; IκBα (official name: NFKBIA), NFKB inhibitor alpha; IKKα (official name: CHUK), component of inhibitor of nuclear factor-kappa B kinase complex; IKKβ (official name: IKBKB), inhibitor of nuclear factor-kappa B kinase subunit beta; PARP, poly(ADP-ribose) polymerase.
Figure 1. Overview of STING signaling in cancer cells. Accumulation of double-stranded DNA (dsDNA) in the cytosol of cancer cells responding to some chemotherapeutics or radiation therapy boosts the enzymatic functions of cyclic GMP-AMP synthase (CGAS), resulting in the cyclic GMP-AMP (cGAMP)-dependent oligomerization and activation of stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) at the endoplasmic reticulum (ER). Activated STING promotes a TANK binding kinase 1 (TAK1)-dependent signal transduction cascade that initiates interferon regulatory factor 3 (IRF3)- and NF-κB-dependent transcription, potentially culminating with the secretion of numerous cytokines including type I interferon (IFN), interleukin 6 (IL-6) and tumor necrosis factor (TNF). CDN, cyclic dinucleotide; IκBα (official name: NFKBIA), NFKB inhibitor alpha; IKKα (official name: CHUK), component of inhibitor of nuclear factor-kappa B kinase complex; IKKβ (official name: IKBKB), inhibitor of nuclear factor-kappa B kinase subunit beta; PARP, poly(ADP-ribose) polymerase.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 408 references

Research works printed but not linked: 2

  1. 10.1043/2010-0454-RAR.1 · doi:10.1043/2010-0454-rar.1
  2. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6:S13–8.

Cited by

See all 239

Metadata

Authors
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E.
Affiliations
  • Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers
  • Université Paris Cité (FR)
  • Inserm (FR)
  • Karolinska University Hospital (SE)
Corresponding author
Kroemer, Guido
Venue
OncoImmunology
Published
2020-01
Volume
9
Issue
1
Pages
1771143-1771143
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W3033852017
Cited by
239
References
410
Citations by year
2026: 7 · 2025: 20 · 2024: 44 · 2023: 56 · 2022: 55 · 2021: 54 · 2020: 3
FWCI
4.10
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • U.S. Department of Defense (#BC180476P1)
  • Leukemia and Lymphoma Society
  • Association pour la Recherche sur le Cancer
  • Seerave Foundation
  • E-Rare
  • European Commission
  • Agence Nationale de la Recherche (ANR18, ANR-16-RHUS-0008, ANR-18-IDEX-0001)
  • Fondation Leducq
  • Institut National de la Santé et de la Recherche Médicale (ANR-18-IDEX-0001)
  • Fondation pour la Recherche Médicale
  • Ligue Contre le Cancer
  • Centre National de la Recherche Scientifique (UMS3655)
  • Institut Universitaire de France (ANR-18-IDEX-0001)
  • Institut National Du Cancer
  • Institut Gustave-Roussy
  • European Research Area Network on Cardiovascular Diseases
  • Weill Cornell Medical College
  • Stand Up To Cancer (ZP-6177)
  • High-end Foreign Experts Recruitment Plan of China (GDW20171100085)
  • Labex Immuno-Oncology ((ANR-18-IDEX-0001))
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
TLR3, TLR3 agonist, cancer immunotherapy, double-stranded RNA, type I interferon, dendritic cells, in situ vaccine, poly(I:C), colorectal cancer, head and neck squamous cell carcinoma, MUC1, PD-1/PD-L1 blockade, innate immunity
MeSH terms
Animals, Dendritic Cells, Humans, Neoplasms, Poly I-C, T-Lymphocytes, Cytotoxic, Toll-Like Receptor 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial watch: TLR3 agonists in cancer therapy. https://app.cochat.ai/papers/10.1080/2162402x.2020.1771143
The paper
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020). Trial watch: TLR3 agonists in cancer therapy. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1771143

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.